PDCD1 and neoplasm: Some studies have shown that the combination of inhibitory receptors, such as the use of anti PD-1/PD-L1 and anti CTLA-4 antibodies, can significantly reverse the exhaustion of T cells and enhance the immune response of various tumor patients28.